Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: cyteir.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2022 | $16.00 | Outperform | Northland Capital |
| 7/13/2021 | $40.00 | Outperform | Wedbush |
| 7/13/2021 | $33.00 | Overweight | Morgan Stanley |
| 7/13/2021 | $23.00 | Buy | B of A Securities |
| 7/13/2021 | $30.00 | Overweight | JP Morgan |
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice President of Regulatory Affairs and Quality. "Krisztina has an impressive track record of leading regulatory functions and development teams at global pharmaceutical companies to successful worldwide product registrations in oncology, demonstrating extensive knowledge of global clinical trial approval processes and requirements, strategic thinking about development plans that maximize the likelihood of successful regulatory appl
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
- Continue to enroll in monotherapy and combination studies with CYT-0851 with potential for interim safety and efficacy data in second half 2022 - Progress achieved in key clinical milestones described in the 2021 IPO: Advanced CYT-0851 monotherapy to Phase 2 and initiated Phase 1 combination therapy study - Projected cash runway into 2024 to support planned R&D and clinical studies - Conference call and webcast scheduled for 4:30 p.m. ET on March 16, 2022 Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the fourth quarter and full year
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results. The live audio webcast can be accessed via the Investor Relations section of the Company's website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir's website for 30 days. About Cyteir Therapeutics, Inc. Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthet
Northland Capital initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $16.00
Wedbush initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $40.00
Morgan Stanley initiated coverage of Cyteir Therapeutics with a rating of Overweight and set a new price target of $33.00
B of A Securities initiated coverage of Cyteir Therapeutics with a rating of Buy and set a new price target of $23.00
JP Morgan initiated coverage of Cyteir Therapeutics with a rating of Overweight and set a new price target of $30.00
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13D/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13D/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G - Cyteir Therapeutics, Inc. (0001662244) (Subject)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
3 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009 initial clinical data showed a promising response and differentiated safety profile R&D Day outlined near-term strategic priorities and highlighted breadth of Bicycle® platform technology and ability to develop highly differentiated precision therapies for cancer and other diseases Stephen Sands appointed to Board of Directors Cash and cash equivalents of $526.4 million as of December 31, 2023, expected to provide financial runway into 2026 Bi
- CYT-0851 demonstrated activity in combination with capecitabine in heavily pretreated platinum-refractory or -resistant ovarian cancer patients with a generally well tolerated safety profile - Overall disease control rate was 91% in the capecitabine combination with a median progression-free survival of 170 days Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination
Cyteir Therapeutics, Inc. ("Cyteir" or the "Company") (NASDAQ:CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir's Board of Directors has determined, after consideration of potential strategic alternatives, it is in the best interests of its shareholders to dissolve Cyteir, liquidate its assets following an orderly wind down of the Company's operations, and return remaining cash to shareholders. CYT-0851 was being evaluated in a Phase 1 combination study with capecitabine or gemcitabine in advanced ovarian cancer and other solid tumors. While durable responses were observed in both combinati
- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of patients - Overall disease control rate was 71.4% with the capecitabine combination and 87.5% with the gemcitabine combination - Enrollment in the Phase 1 dose escalation study continues with preliminary data expected in mid-2023 Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate Tra
- Enrollment continuing in trials with CYT-0851 in combination with capecitabine or gemcitabine with data expected in mid-2023 - Ended first quarter of 2023 with approximately $137.2 million in cash Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights. "We have made encouraging progress enrolling patients in the CYT-0851 Phase 1 combination trial with capecitabine and gemcitabine, while maintaining our strong financial discipline," said Markus Renschler, MD, President and Chief Executive Officer of Cyteir. "We look forward
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent operational highlights. "We continue to be encouraged by the early clinical activity of CYT-0851 in ovarian cancer and are committed to bringing CYT-0851 to patients," said Markus Renschler, MD, President and Chief Execu
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department, to oversee the company's overall financial operations, and to help drive the long-term business and financial strategy of Cyteir, reporting directly to the President & CEO. "When Dave joined Cyteir in 2020, he brought a wealth of experience that helped us internalize the finance function, prepare for our IPO, and operate as a public company. His strong financial foundation and disciplined approach to resource m
- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash runway into 2026 Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer. The prioritization follows encouraging preliminary clinical activity in a small number of patients observed in the Phase 1 do
- Initial data from CYT-0851 monotherapy solid tumor Phase 2 cohorts are now expected in first quarter of 2023 - Initial data from Phase 1 combination solid tumor cohorts are expected in first half of 2023 - Ended quarter with approximately $153.9 million in cash Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights. "The Cyteir team continues to make progress with CYT-0851 in the clinic and understanding the optimal target population that will
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to
B of A Securities analyst Tazeen Ahmad downgrades Cyteir Therapeutics (NASDAQ:CYT) from Neutral to Underperform and announces $3 price target.
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer" (Poster: LB_A13) at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston, Massachusetts.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.93% to 34,439.75 while the NASDAQ rose 1.54% to 13,800.92. The S&P 500, also rose, gaining, 1.32% to 4,454.48. Check This Out: Top 5 Tech And Telecom Stocks That Are Ticking Portfolio Bombs Leading and Lagging Sectors Information technology shares jumped by 1.7% on Friday. In trading on Friday, real estate shares fell by 0.3%. Top Headline The total number of active U.S. oil rigs fell by 1 to 545 rigs this week, Baker Hughes Inc reported. Equities Trading UP Renalytix Plc (NASDAQ:RNLX) shares shot up 44% to $2.92 after the company received FDA De N
Gainers Baudax Bio (NASDAQ:BXRX) shares increased by 130.7% to $1.2 during Friday's regular session. Trading volume for this security as of 13:37 EST is 93.9 million, which is 10027.5% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million. CymaBay Therapeutics (NASDAQ:CBAY) stock increased by 41.61% to $11.1. The current volume of 13.9 million shares is 855.6% of CymaBay Therapeutics's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $1.0 billion. Renalytix (NASDAQ:RNLX) stock increased by 41.14% to $2.92. Trading volume for this security as of 13:37 EST is 29.7 m
Gainers Addentax Group Corp. (NASDAQ:ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) surged 40% to $10.97. Cyteir Therapeutics, Inc. (NASDAQ:CYT) shares gained 38% to $2.6487. Cyteir Therapeutics reported discontinuation of CYT-0851 development program and planned liquidation and dissolution. TOP Financial Group Limited (NASDAQ:TOP) shares gained 32.2% to $10.31 after the company reported FY23 financial results. Renalytix Plc (NASDAQ:RNLX) shares jumped 31% to $2.66 after the company received FDA De Novo marketing autho
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.62% to 34,333.42 while the NASDAQ rose 1.37% to 13,777.52. The S&P 500, also rose, gaining, 1.04% to 4,441.95. Check This Out: Top 5 Tech And Telecom Stocks That Are Ticking Portfolio Bombs Leading and Lagging Sectors Information technology shares jumped by 1.7% on Friday. In trading on Friday, real estate shares rose by just 0.2%. Top Headline The Core Personal Consumption Expenditure (PCE) price index, the Federal Reserve's preferred measure of inflation, rose 4.6% year-over-year in May 2023, slightly down from both the previous and expected 4.7%, the U
Gainers Renalytix (NASDAQ:RNLX) shares moved upwards by 38.6% to $2.87 during Friday's pre-market session. The company's market cap stands at $134.5 million. Cyteir Therapeutics (NASDAQ:CYT) stock rose 28.12% to $2.46. The market value of their outstanding shares is at $87.3 million. CymaBay Therapeutics (NASDAQ:CBAY) stock increased by 22.7% to $9.62. The company's market cap stands at $938.0 million. CytomX Therapeutics (NASDAQ:CTMX) stock rose 21.98% to $1.72. The company's market cap stands at $114.1 million. Baudax Bio (NASDAQ:BXRX) stock increased by 21.14% to $0.63. The market value of their outstanding shares is at $3.8 million. Alvotech (NASDAQ:ALVO) stock rose 11.59% to $7.7.
15-12G - Cyteir Therapeutics, Inc. (0001662244) (Filer)
S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)
S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)
S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)
AW - Cyteir Therapeutics, Inc. (0001662244) (Filer)
AW - Cyteir Therapeutics, Inc. (0001662244) (Filer)
AW - Cyteir Therapeutics, Inc. (0001662244) (Filer)
8-K - Cyteir Therapeutics, Inc. (0001662244) (Filer)
POS AM - Cyteir Therapeutics, Inc. (0001662244) (Filer)
POS AM - Cyteir Therapeutics, Inc. (0001662244) (Filer)